TEVA · ISSUER CIK 818686
TEVA PHARMACEUTICAL INDUSTRIES LTD
Between Jul 31, 2026 and Oct 28, 2026, 8 TEVA PHARMACEUTICAL INDUSTRIES LTD insiders reported $0.00 of open-market purchases and $17.0M of sales on SEC Form 4.
↗8 insiders filed
Original Form 4 filings from Jul 31, 2026 to Oct 28, 2026. 3 of 8 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$17.0MInsider selling
−$17.0MNet open-market
Sep 22, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 22, 202617:01 | Sep 18, 2026 | TEVA | Interim Chief Legal Officer | S · Sell | $38.85 | −7,342 | 8,500 | -46% | −$285K | ||
| Sep 22, 202617:01 | Sep 18, 2026 | TEVA | Interim Chief Legal Officer | M · Exercise | $34.70 | +4,503 | 15,842 | +40% | $156K | ||
| Sep 22, 202616:21 | Sep 18, 2026 | TEVA | Director | S · Sell | $39.06 | −367,600 | 0 | -100% | −$14.4M | ||
| Aug 25, 202616:05 | Aug 21, 2026 | TEVA | Chief Accounting Officer | S · Sell | $37.62 | −9,445 | 13,071 | -42% | −$355K | ||
| Aug 25, 202616:05 | Aug 21, 2026 | TEVA | Chief Accounting Officer | M · Exercise | $19.61 | +2,500 | 15,571 | +19% | $49K | ||
| Aug 25, 202616:03 | Aug 21, 2026 | TEVA | Director | S · Sell | $37.25 | −415 | 111,986 | -0% | −$15K | ||
| Aug 19, 202616:00 | Aug 17, 2026 | TEVA | EVP, Business Development | S · Sell10b5-1 | $36.57 | −18,600 | 25,591 | -42% | −$680K | ||
| Aug 10, 202606:07 | Aug 5, 2026 | TEVA | Director | S · SellLate 5d | $34.87 | −17 | 73,247 | -0% | −$592.71 | ||
| Aug 5, 202616:04 | Aug 3, 2026 | TEVA | See "Remarks" | S · Sell10b5-1 | $34.88 | −12,827 | 6,774 | -65% | −$447K | ||
| Aug 5, 202616:04 | Aug 3, 2026 | TEVA | See "Remarks" | M · Exercise10b5-1 | — | +12,827 | 19,601 | +189% | — | ||
| Aug 5, 202616:02 | Aug 3, 2026 | TEVA | See "Remarks" | S · Sell10b5-1 | $34.88 | −25,578 | 134,877 | -16% | −$892K | ||
| Aug 5, 202616:02 | Aug 3, 2026 | TEVA | See "Remarks" | M · Exercise10b5-1 | — | +52,744 | 160,455 | +49% | — |